Lercanidipine Eg (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. By preventing calcium entry, it causes dose‑dependent vasodilation of peripheral arteries, which decreases peripheral resistance and results in a reduction of arterial blood pressure.

The appropriate dose of Lercanidipine Eg is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant therapies. The prescriber will select the starting dose and any subsequent adjustments.

The safety of lercanidipine in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians usually avoid its use unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lercanidipine, as a dihydropyridine calcium‑channel blocker, primarily induces arterial vasodilation, whereas beta‑blockers reduce cardiac output and ACE inhibitors block the renin‑angiotensin system. Lercanidipine often provides a smoother blood‑pressure reduction with a lower incidence of reflex tachycardia compared with some other calcium‑channel blockers.

Lercanidipine Eg tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in a humid environment or expose the product to excessive heat.

Lercanidipine Eg is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as angioedema, and cardiac conduction disturbances like heart block. Patients should seek immediate medical attention if they experience symptoms such as faintness, chest pain, jaundice, rash, or irregular heartbeat.

Lercanidipine is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. Caution is advised in individuals with severe aortic stenosis, unstable angina, or those taking strong CYP3A4 inhibitors, as these conditions may increase the risk of adverse effects.